The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2016 | How to generate an anticancer immune response in multiple myeloma
Paula Rodríguez, MD, PhD from the University Clinic of Navarra, Pamplona, Spain gives an overview of her talk on anticancer immunity in multiple myeloma (MM) held at the 2016 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. Cancer cells have varied mechanisms to evade immune control and the basis of anticancer immunity is to disrupt these mechanisms. According to Dr Rodríguez, there are four approaches to disrupt these mechanisms: monoclonal antibodies, boosting the effector cells with adoptive therapy such as CAR T-cells, vaccination or using drugs like checkpoint inhibitors to overcome the immune suppression. Dr Rodríguez further explains how the immune suppression can be overcome.
